Dr Antonio Jimenez Jimenez speaks to ecancer about results from the NMDP sponsored ACCESS study.

The results from this trial show that post-transplant cyclophosphamide (PTCy) based GVHD prophylaxis enables excellent outcomes after mismatched unrelated donor haematopoietic cell transplantation, even with <7/8 HLA matching.

Adults receiving 4–6/8 MMUD peripheral blood stem cell grafts achieved 1-year overall survival exceeding 80%, with relapse, non-relapse mortality, and GVHD rates comparable to those seen in 7/8 MMUD recipients across conditioning intensities.

These findings suggest that strict HLA matching may be less critical when PTCy is used, supporting broader donor eligibility and improved transplant access for racially and ethnically diverse patients.